Reliability of anti-HCV antibody screening systems. 1st Generation EIA, 2nd generation PHA, PA and a new EIA kit using synthetic paptide (AR142)- based on nested polymerase chain reaction.

概要

論文の詳細を見る
In November 1989, we started anti-HCV antibody screening on all of donor bloods with 1st generation EIA kits (Ortho Diagnostic System K. K.) for the purpose of preventing recipients against post-transfusion hepatitis. But, it has been known that this EIA system was not enough to detect all of anti-HCV antibody positive samples.Recently, two agglutination methods (PHA and PA), so-called 2nd generation anti-HCV antibody testing reagent, were developed and became enable to use. We tried to evaluate whether or not these methods were useful for screening test on blood donors.We compared these two agglutination methods to 1st generation EIA on 1723 donor samples. We also tried polymerase chain reaction as confirmatory test to prove HCV-RNA, and RIBA II test as supplementary test on 61 samples which were positive with, at least, one of three methods. Furthermore, we tried to evaluate a new EIA kit (Kuraray Co.) using synthetic peptide (AR142) on same samples.Although two agglutination methods detected all of 26 PCR positive samples, only 17 and 21 samples out of them were detected by 1st generation EIA and synthetic peptide EIA respectively.These results revealed that PHA and PA were superior to the 1st generation EIA for screening system of anti-HCV antibody in blood centers.
一般社団法人日本輸血・細胞治療学会の論文